Prediction: The Next Eli Lilly Might Already Be Trading Under $50

Eli Lilly (NYSE: LLY) produced exceptional returns over the long run and is now the largest pharmaceutical company in the world by market cap, largely thanks to its work in diabetes drugs and, more recently, weight management. The company's shares are currently trading at about $860, but what if we could invest in the next Eli Lilly now at a fraction of that price?One strong candidate for future pharmaceutical greatness is Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech with large-cap ambitions. Viking Therapeutics doesn't have any products on the market yet, but its leading drug candidate, VK2735, looks promising. This investigational weight loss medicine mimics the actions of the GLP-1 and GIP hormones, both of which help control blood sugar levels. So far, the only dual GLP-1/GIP agonist approved by the Food and Drug Administration is Eli Lilly's tirzepatide, a therapy that is smashing pharmaceutical industry sales records, marketed as Mounjaro and Zepbound.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool